Your Shopping Cart Is Empty
| Report Code: A00295 | Dec 2021 | Pages: 254 | ||
| Tables: 99 | Charts: 49 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Liver Disease Treatment Market
Request Now !The global liver disease treatment market size was valued at $20,673.70 million in 2020, and is estimated to reach $36,455.70 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030. Liver is the largest solid organ and largest gland in the human body. In addition, it suffers from various ailments, which are treated using different types of products. In addition, these products include different kinds of drugs and vaccines. For instance, anti-viral drugs are used to treat hepatitis that cause liver inflammation. In addition, hepatitis is fatal, and thus sometimes requires liver transplant. In such cases, immunosuppressant drugs that prevent rejection of transplanted liver in the body are used.
Furthermore, immunoglobulin is used in treatment of certain types of hepatitis. Moreover, vaccines are used to prevent hepatitis viral infection. For instance, vaccines are available for prevention of hepatitis A, B, and C. Furthermore, other products such as corticosteroids are used in the treatment of liver related autoimmune diseases such as autoimmune hepatitis. Thus, there are various liver related conditions such as hepatitis, autoimmune diseases, non-alcoholic fatty liver, cancer, and genetic disorders, which are treated by using different types of products such as anti-viral drugs, immunosuppressants, vaccines immunoglobulins, corticosteroids, targeted therapy, and chemotherapy.
Increase in prevalence of liver diseases such as the non-alcoholic fatty liver disease (NAFLD), liver cirrhosis, hepatitis, alcoholic hepatitis, and liver cancer, globally is majorly due to unhealthy lifestyle and alcohol consumption. In addition, rise in geriatric population globally further leads to disease dysfunction. Thus, there has been an increase in hospital admissions due to various abovementioned liver diseases as well certain genetic disorders, which are hereditary.
Considerable rise in alcohol consumption is one of the major reasons that leads to liver disorders, as some liver cells die as a result of the alcohol filtering process, thus leading to scar tissue build up in the liver. Although the liver can regenerate new cells, heavy drinking can impair this function and may lead to permanently damage. Alcohol-related liver disease also known as alcoholic liver disease is a phrase for three liver diseases linked to heavy drinking: alcoholic fatty liver, alcoholic hepatitis, and alcoholic cirrhosis.
In addition, poor eating habits and unhealthy lifestyle causes weight gain further leading to obesity. Obesity, followed by alcoholism, is the major cause of fatty liver disease in adults. Fat accumulates in the liver as a result of being overweight or obese. This causes liver scarring and chronic inflammation (also known as cirrhosis). Obesity is closely associated to non-alcoholic fatty liver disease. Insulin resistance and inflammatory signals are caused by excess fat. Fatty liver disease is more likely to occur in patients who have hypertension (high blood pressure), high cholesterol, are overweight or obese, and have diabetes or insulin resistance. However, stringent regulatory approvals for novel drugs & vaccines and resistance to certain antiviral drugs restrain the market growth.
Furthermore, geriatric population is more prone to liver diseases compared to adults, owing to their low immunity levels. In addition, ageing has been shown to enhance vulnerability to acute liver injury. Initiatives taken by various governments, not-for-profit organizations, key players of the market for hepatic disorders play a pivotal role in increasing awareness about liver diseases around the world.
Thus, all these factors collectively provide opportunity for investments in R&D activities for the development of liver disease treatment solutions for better drug efficacy and safe therapy for already existing drugs as well as upcoming new molecular entities, which further drives the growth of the liver disease treatment market.
In addition, the COVID-19 outbreak is anticipated to have a moderate impact, owing to decline in demand for various drugs used in liver treatments. Furthermore, other factors responsible for the impact on the market include limited availability of medical care, shortage of healthcare staff, rise in burden of COVID-19 related hospitalization, and availability of drugs and vaccines. However, as the vaccinations for COVID-19 are available various governments are working to ensure undisrupted supply of life saving drugs and vaccines. Thus, this is expected to lead to a stabilization in the market overtime
Conversely, research studies and activities, including clinical trials for the efficacy and safety, for the treatment of liver disease by various researchers, companies, and government boosted the liver disease treatment market.
Furthermore, untapped, emerging markets are expected to offer potential growth opportunities, due to improved healthcare infrastructure, increase in unmet healthcare needs, and rise in R&D activities. In addition, various technological advancements in drug delivery is an emerging opportunity for key players to invest in the liver disease treatment market.
The global liver disease treatment market is segmented into treatment type, disease type, and region. On the basis of treatment, the market is segregated into antiviral drugs, immunosuppressants, vaccines, immunoglobulins, corticosteroids, targeted therapy, and chemotherapy drugs.
By disease type, the market is segmented into hepatitis, autoimmune diseases, non-alcoholic fatty liver disease (NAFLD), cancer, genetic disorders, and others.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Depending on the treatment type, the antiviral drugs segment dominated the market in 2020, and is expected to continue this trend during the forecast period, due to increase in prevalence of viral liver diseases.
By disease type, the hepatitis segment exhibited the highest growth in 2020, and is expected to continue this trend during the forecast period.
North America accounted for a majority of the global liver disease treatment market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to increase in consumption of alcohol, unhealthy lifestyle leading to obesity & weight gain, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities, surge in liver diseases, unmet medical demands, and increase in investments in the healthcare sector in the region.
Key Benefits for Stakeholders
Liver Disease Treatment Market Report Highlights
| Aspects | Details |
|---|---|
| By TREATMENT TYPE |
|
| By DISEASE TYPE |
|
| By Region |
|
| Key Market Players | ELI LILLY AND COMPANY, BRISTOL-MYERS SQUIBB, ABBVIE INC., VIATRIS INC., ASTELLAS PHARMA INC., EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA), MERCK & CO. INC., F. HOFFMANN-LA ROCHE AG, ABBOTT LABORATORIES, GILEAD SCIENCES, INC. |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profile in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET LANDSCAPE
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.3.Porter’s five forces analysis
3.4.Top player positioning, 2020
3.5.Market dynamics
3.5.1.Drivers
3.5.1.1.Rise in incidence of liver diseases
3.5.1.2.Increased alcohol consumption and poor dietary habits
3.5.1.3.Surge in geriatric population
3.5.1.4.Increase in government and nongovernment awareness programs
3.5.2.Restraints
3.5.2.1.Stringent regulatory approvals related to liver disease treatment drugs and vaccines
3.5.2.2.Resistance to antiviral drugs used in treatment of hepatitis B and hepatitis C
3.5.3.Opportunity
3.5.3.1.Presence of strong pipeline products
3.6.Impact analysis
3.7.Impact analysis of COVID-19 on the liver disease treatment market
CHAPTER 4:LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE
4.1.Overview
4.1.1.Market size and forecast
4.2.Antiviral drugs
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Immunosuppressants
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by region
4.3.3.Market analysis, by country
4.4.Vaccines
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by region
4.4.3.Market analysis, by country
4.5.Immunoglobulins
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Corticosteroids
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
4.7.Targeted therapy
4.7.1.Key market trends, growth factors, and opportunities
4.7.2.Market size and forecast, by region
4.7.3.Market analysis, by country
4.8.Chemotherapy
4.8.1.Key market trends, growth factors, and opportunities
4.8.2.Market size and forecast, by region
4.8.3.Market analysis, by country
CHAPTER 5:LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE
5.1.Overview
5.1.1.Market size and forecast
5.2.Hepatitis
5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country
5.3.Autoimmune diseases
5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country
5.4.Non-alcoholic fatty liver disease (NAFLD)
5.4.1.Market size and forecast, by region
5.4.2.Market analysis, by country
5.5.Cancer
5.5.1.Market size and forecast, by region
5.5.2.Market analysis, by country
5.6.Genetic disorders
5.6.1.Market size and forecast, by region
5.6.2.Market analysis, by country
5.7.Others
5.7.1.Market size and forecast, by region
5.7.2.Market analysis, by country
CHAPTER 6:LIVER DISEASE TREATMENT MARKET, BY REGION
6.1.Overview
6.1.1.Market size and forecast
6.2.North America
6.2.1.Key market trends, growth factors, and opportunities
6.2.2.North America liver disease treatment market, by treatment type
6.2.3.North America liver disease treatment market, by disease type
6.2.4.Market size and forecast, by country
6.2.4.1.U.S.
6.2.4.1.1.U.S. liver disease treatment market, by treatment type
6.2.4.1.2.U.S. liver disease treatment market, by disease type
6.2.4.2.Canada
6.2.4.2.1.Canada liver disease treatment market, by treatment type
6.2.4.2.2.Canada liver disease treatment market, by disease type
6.2.4.3.Mexico
6.2.4.3.1.Mexico liver disease treatment market, by treatment type
6.2.4.3.2.Mexico liver disease treatment market, by disease type
6.3.Europe
6.3.1.Key market trends, growth factors, and opportunities
6.3.2.Europe liver disease treatment market, by treatment type
6.3.3.Europe liver disease treatment market, by disease type
6.3.4.Market size and forecast, by country
6.3.4.1.Germany
6.3.4.1.1.Germany liver disease treatment market, by treatment type
6.3.4.1.2.Germany liver disease treatment market, by disease type
6.3.4.2.France
6.3.4.2.1.France liver disease treatment market, by treatment type
6.3.4.2.2.France liver disease treatment market, by disease type
6.3.4.3.UK
6.3.4.3.1.UK liver disease treatment market, by treatment type
6.3.4.3.2.UK liver disease treatment market, by disease type
6.3.4.4.Italy
6.3.4.4.1.Italy liver disease treatment market, by treatment type
6.3.4.4.2.Italy liver disease treatment market, by disease type
6.3.4.5.Spain
6.3.4.5.1.Spain liver disease treatment market, by treatment type
6.3.4.5.2.Spain liver disease treatment market, by disease type
6.3.4.6.Rest of Europe
6.3.4.6.1.Rest of Europe liver disease treatment market, by treatment type
6.3.4.6.2.Rest of Europe liver disease treatment market, by disease type
6.4.Asia-Pacific
6.4.1.Key market trends, growth factors, and opportunities
6.4.2.Asia-Pacific liver disease treatment market, by treatment type
6.4.3.Asia-Pacific liver disease treatment market, by disease type
6.4.4.Market size and forecast, by country
6.4.4.1.Japan
6.4.4.1.1.Japan liver disease treatment market, by treatment type
6.4.4.1.2.Japan liver disease treatment market, by disease type
6.4.4.2.China
6.4.4.2.1.China liver disease treatment market, by treatment type
6.4.4.2.2.China liver disease treatment market, by disease type
6.4.4.3.Australia
6.4.4.3.1.Australia liver disease treatment market, by treatment type
6.4.4.3.2.Australia liver disease treatment market, by disease type
6.4.4.4.India
6.4.4.4.1.India liver disease treatment market, by treatment type
6.4.4.4.2.India liver disease treatment market, by disease type
6.4.4.5.South Korea
6.4.4.5.1.South Korea liver disease treatment market, by treatment type
6.4.4.5.2.South Korea liver disease treatment market, by disease type
6.4.4.6.Rest of Asia-Pacific
6.4.4.6.1.Rest of Asia-Pacific liver disease treatment market, by treatment type
6.4.4.6.2.Rest of Asia-Pacific liver disease treatment market, by disease type
6.5.LAMEA
6.5.1.Key market trends, growth factors, and opportunities
6.5.2.LAMEA liver disease treatment market, by treatment type
6.5.3.LAMEA liver disease treatment market, by disease type
6.5.4.LAMEA liver disease treatment market, by country
6.5.4.1.Brazil
6.5.4.1.1.Brazil liver disease treatment market, by treatment type
6.5.4.1.2.Brazil liver disease treatment market, by disease type
6.5.4.2.Saudi Arabia
6.5.4.2.1.Saudi Arabia liver disease treatment market, by treatment type
6.5.4.2.2.Saudi Arabia liver disease treatment market, by disease type
6.5.4.3.South Africa
6.5.4.3.1.South Africa liver disease treatment market, by treatment type
6.5.4.3.2.South Africa liver disease treatment market, by disease type
6.5.4.4.Rest of LAMEA
6.5.4.4.1.Rest of LAMEA liver disease treatment market, by treatment type
6.5.4.4.2.Rest of LAMEA liver disease treatment market, by disease type
CHAPTER 7:COMPANY PROFILES
7.1.ABBVIE INC.
7.1.1.Company overview
7.1.2.Company snapshot
7.1.3.Operating business segments
7.1.4.Product portfolio
7.1.5.Business performance
7.1.6.Key strategic moves and developments
7.2.ABBOTT LABORATORIES
7.2.1.Company overview
7.2.2.Company snapshot
7.2.3.Operating business segments
7.2.4.Product portfolio
7.2.5.Business performance
7.3.ASTELLAS PHARMA INC.
7.3.1.Company overview
7.3.2.Company snapshot
7.3.3.Operating business segments
7.3.4.Product portfolio
7.3.5.Business performance
7.4.BRISTOL-MYERS SQUIBB
7.4.1.Company overview
7.4.2.Company snapshot
7.4.3.Operating business segments
7.4.4.Product portfolio
7.4.5.Business performance
7.5.ELI LILLY AND COMPANY
7.5.1.Company overview
7.5.2.Company snapshot
7.5.3.Operating business segments
7.5.4.Product portfolio
7.5.5.Business performance
7.5.6.Key strategic moves and developments
7.6.EMERGENT BIOSOLUTIONS INC. (CANGENE BIOPHARMA)
7.6.1.Company overview
7.6.2.Company snapshot
7.6.3.Operating business segments
7.6.4.Product portfolio
7.6.5.Business performance
7.7.F. HOFFMANN-LA ROCHE AG
7.7.1.Company overview
7.7.2.Company snapshot
7.7.3.Operating business segments
7.7.4.Product portfolio
7.7.5.Business performance
7.7.6.Key strategic moves and developments
7.8.GILEAD SCIENCES, INC.
7.8.1.Company overview
7.8.2.Company snapshot
7.8.3.Operating business segments
7.8.4.Product portfolio
7.8.5.Business performance
7.8.6.Key strategic moves and developments
7.9.MERCK & CO. INC.
7.9.1.Company overview
7.9.2.Company snapshot
7.9.3.Operating business segments
7.9.4.Product portfolio
7.9.5.Business performance
7.9.6.Key strategic moves and developments
7.10.VIATRIS INC.
7.10.1.Company overview
7.10.2.Company snapshot
7.10.3.Operating business segments
7.10.4.Product portfolio
7.10.5.Business performance
LIST OF TABLES
TABLE 01.LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 02.ANTIVIRAL DRUGS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 03.IMMUNOSUPPRESSANTS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 04.VACCINES MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 05.IMMUNOGLOBULINS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 06.CORTICOSTEROIDS MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 07.TARGETED THERAPY MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 08.CHEMOTHERAPY MARKET FOR LIVER DISEASE TREATMENT, BY REGION, 2020-2030 ($MILLION)
TABLE 09.LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020–2030 ($MILLION)
TABLE 10.LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY REGION, 2020–2030 ($MILLION)
TABLE 11.LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2020–2030($MILLION)
TABLE 12.LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), BY REGION, 2020–2030($MILLION)
TABLE 13.LIVER DISEASE TREATMENT MARKET FOR CANCER, BY REGION, 2020–2030($MILLION)
TABLE 14.LIVER DISEASE TREATMENT MARKET FOR GENETIC DISORDERS, BY REGION, 2020–2030($MILLION)
TABLE 15.LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY REGION, 2020–2030($MILLION)
TABLE 16.LIVER DISEASE TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 17.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 18.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 19.NORTH AMERICA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 20.U.S. LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 21.U.S. LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 22.CANADA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 23.CANADA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 24.MEXICO LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 25.MEXICO LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 26.EUROPE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 27.EUROPE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 28.EUROPE LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 29.GERMANY LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 30.GERMANY LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 31.FRANCE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 32.FRANCE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 33.UK LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 34.UK LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 35.ITALY LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 36.ITALY LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 37.SPAIN LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 38.SPAIN LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 39.REST OF EUROPE LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 40.REST OF EUROPE LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 41.ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 42.ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 43.ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 44.JAPAN LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 45.JAPAN LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 46.CHINA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 47.CHINA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 48.AUSTRALIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 49.AUSTRALIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 50.INDIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 51.INDIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 52.SOUTH KOREA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 53.SOUTH KOREA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 54.REST OF ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 55.REST OF ASIA-PACIFIC LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 56.LAMEA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 57.LAMEA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 58.LAMEA LIVER DISEASE TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
TABLE 59.BRAZIL LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 60.BRAZIL LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 61.SAUDI ARABIA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 62.SAUDI ARABIA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 63.SOUTH AFRICA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 64.SOUTH AFRICA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 65.REST OF LAMEA LIVER DISEASE TREATMENT MARKET, BY TREATMENT TYPE, 2020-2030 ($MILLION)
TABLE 66.REST OF LAMEA LIVER DISEASE TREATMENT MARKET, BY DISEASE TYPE, 2020-2030 ($MILLION)
TABLE 67.ABBVIE: COMPANY SNAPSHOT
TABLE 68.ABBVIE: PRODUCT SEGMENTS
TABLE 69.ABBVIE: PRODUCT PORTFOLIO
TABLE 70.ABBVIE: KEY DEVELOPMENTS
TABLE 71.ABBOTT: COMPANY SNAPSHOT
TABLE 72.ABBOTT: OPERATING SEGMENTS
TABLE 73.ABBOTT: PRODUCT PORTFOLIO
TABLE 74.ASTELLAS: COMPANY SNAPSHOT
TABLE 75.ASTELLAS: OPERATING SEGMENTS
TABLE 76.ASTELLAS: PRODUCT PORTFOLIO
TABLE 77.BRISTOL: COMPANY SNAPSHOT
TABLE 78.BRISTOL: PRODUCT SEGMENTS
TABLE 79.BRISTOL: PRODUCT PORTFOLIO
TABLE 80.LILLY: COMPANY SNAPSHOT
TABLE 81.LILLY: OPERATING SEGMENTS
TABLE 82.LILLY: PRODUCT PORTFOLIO
TABLE 83.ELI LILLY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 84.EMERGENT SOLUTIONS: COMPANY SNAPSHOT
TABLE 85.EMERGENT SOLUTIONS: OPERATING SEGMENTS
TABLE 86.EMERGENT SOLUTIONS: PRODUCT PORTFOLIO
TABLE 87.ROCHE: COMPANY SNAPSHOT
TABLE 88.ROCHE: PRODUCT SEGMENTS
TABLE 89.ROCHE: PRODUCT PORTFOLIO
TABLE 90.ROCHE: KEY DEVELOPMENTS
TABLE 91.GILEAD: COMPANY SNAPSHOT
TABLE 92.GILEAD: OERATING SEGMENT
TABLE 93.GILEAD: PRODUCT PORTFOLIO
TABLE 94.MERCK: COMPANY SNAPSHOT
TABLE 95.MERCK: OPERATING SEGMENTS
TABLE 96.MERCK: PRODUCT PORTFOLIO
TABLE 97.VIATRIS: COMPANY SNAPSHOT
TABLE 98.VIATRIS: OPERATING BUSINESS SEGMENTS
TABLE 99.VIATRIS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL LIVER DISEASE TREATMENT MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018–2021
FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018–2021
FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018–2021
FIGURE 06.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 07.HIGH BARGAINING POWER OF BUYERS
FIGURE 08.HIGH THREAT OF SUBSTITUTES
FIGURE 09.HIGH THREAT OF NEW ENTRANTS
FIGURE 10.HIGH INTENSITY OF RIVALRY
FIGURE 11.TOP PLAYER POSITIONING, 2020
FIGURE 12.IMPACT ANALYSIS
FIGURE 13.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR ANTIVIRAL DRUGS, BY COUNTRY, 2020-2030 (%)
FIGURE 14.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR IMMUNOSUPPRESSANTS, BY COUNTRY, 2020-2030 (%)
FIGURE 15.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR VACCINES, BY COUNTRY, 2020-2030 (%)
FIGURE 16.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR IMMUNOGLOBULINS, BY COUNTRY, 2020-2030 (%)
FIGURE 17.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2020-2030 (%)
FIGURE 18.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR TARGETED THERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 19.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2020-2030 (%)
FIGURE 20.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR HEPATITIS, BY COUNTRY, 2020-2030 (%)
FIGURE 21.COMPARATIVE ANALYSIS OF FOR LIVER DISEASE TREATMENT MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2020-2030 (%)
FIGURE 22.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), BY COUNTRY, 2020-2030 (%)
FIGURE 23.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR CANCER, BY COUNTRY, 2020-2030 (%)
FIGURE 24.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2020-2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF LIVER DISEASE TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2020-2030 (%)
FIGURE 26.ABBVIE: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.ABBVIE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 28.ABBOTT: NET SALES, 2018–2020 ($MILLION)
FIGURE 29.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 30.ABBOTT: REVENUE SHARE BY REGION, 2020(%)
FIGURE 31.ASTELLAS: NET SALES, 2018–2020 ($MILLION)
FIGURE 32.ASTELLAS: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 33.ASTELLAS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 34.BRISTOL: NET SALES, 2018–2020 ($MILLION)
FIGURE 35.BRISTOL: REVENUE SHARE BY REGION, 2020(%)
FIGURE 36.LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.LILLY: REVENUE SHARE BY REGION, 2020(%)
FIGURE 38.EMERGENT SOLUTIONS: NET SALES, 2019–2020 ($MILLION)
FIGURE 39.EMERGENT SOLUTIONS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 40.EMERGENT SOLUTIONS: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 41.ROCHE: NET SALES, 2018–2020 ($MILLION)
FIGURE 42.ROCHE: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.ROCHE: REVENUE SHARE BY REGION, 2020(%)
FIGURE 44.GILEAD: NET SALES, 2018–2020 ($MILLION)
FIGURE 45.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 46.MERCK: REVENUE SHARE, BY SEGMENTS, 2020 (%)
FIGURE 47.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 48.VIATRIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 49.VIATRIS: REVENUE SHARE, BY REGION, 2020 (%)
This section provides the opinions of the top level CXOs in the global liver disease treatment market. According to the insights of CXOs, increase in geriatric population, increased alcohol consumption, unhealthy lifestyle, unhealthy eating habits leading to obesity, all leading to wide range of liver disorders are expected to significantly boost the growth of the liver disease treatment market.
The CXOs further added that increase in prevalence of chronic diseases which affects the liver, surge in liver cancer cases, and global rise of hepatitis cases escalate the growth of the market. Moreover, rise in drug discovery & development and introduction of novel drugs for the treatment of liver diseases notably contribute toward the growth of the market.
Furthermore, experts of key companies believe surge in geriatric population, which is more prone to liver diseases, rise in awareness toward early detection and treatment of liver diseases, and increase in government programs designed to spread awareness related to hepatitis prevention fuel the growth of the liver disease treatment market.
The market gains interest of healthcare companies, owing to surge in R&D and increase in focus in adoption of liver disease treatment in research centers.
North America is expected to witness highest growth, in terms of revenue, owing to increase in prevalence of chronic diseases, rise in consumption of alcohol, unhealthy lifestyle leading to obesity and weight gain, presence of key players, and rise healthcare expenditure in the region. However, Asia-Pacific is anticipated to witness notable growth, owing to rise in R&D activities leading to clinical trials for various diseases, surge in liver diseases, unmet medical demands, and due to the continuous government support for pharmaceutical and biotechnology R&D, increase in public–private investments, and rise in number of translational research activities in the healthcare sector.
A. The total market value of liver disease treatment market is $20,673.70 million in 2020.
A. The forecast period for liver disease treatment market is 2021 to 2030
A. The market value of liver disease treatment market in 2021 is $22,100.20 million.
A. The base year is 2020 in liver disease treatment market
A. Top companies such as AbbVie Inc., Abbott Laboratories, Astellas Pharma Inc., Bristol Myers Squibb, Eli Lilly and Company, F. Hoffman-LA Roche, Emergent BioSolutions (Cangene bioPharma), Gilead Sciences, Inc., Merck & Co., Inc. (Merck Sharp & Dohme Corp.) and Viatris Inc., held a high market position in 2020.
A. Antiviral drugs segment dominated the global market in 2020, and expected to continue this trend throughout the forecast period due to their increase in prevalence of virus infected liver diseaes, specifically surge of hepatitis cases is expected to drive the segment
A. Increase in prevalence of liver diseases, increase in alcohol consumption, advanced infrastructure for research & development and investments in healthcare is anticipated to drive the market in the forecast period.
A. North America is projected to account for a major share of the global liver disease treatment market during the forecast period. Asia-Pacific is projected to offer lucrative oppurtunities due to increase in prevalence of liver diseases, rise in investments for drug discovery in the R & D sector due to presence of key players across the region.
Start reading instantly.
This Report and over 67,068+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report